Drugs /

capivasertib

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
A novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components. By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be used as monotherapy or combination therapy for a variety of human cancers.

Clinical Trials

View Clinical Trials for capivasertib

Capivasertib has been investigated in 20 clinical trials, of which 18 are open and 2 are closed. Of the trials investigating capivasertib, 7 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 6 are phase 2 (6 open), and 4 are phase 3 (4 open).

HER2 Deficient Expression, HER2 Negative, and ER Positive are the most frequent biomarker inclusion criteria for capivasertib clinical trials.

Breast carcinoma, malignant solid tumor, and prostate carcinoma are the most common diseases being investigated in capivasertib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Capivasertib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Capivasertib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating capivasertib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
akt inhibitor azd5363, capivasertib, azd5363
Drug Categories [2]:
AKT inhibitors, Serine/threonine kinase inhibitors
Drug Target(s) [2]:
AKT1, AKT2, AKT3
NCIT ID [1]:
C102564

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.